Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2
- PMID: 14751571
- DOI: 10.1016/j.bone.2003.09.009
Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2
Abstract
We have previously shown that a subcutaneous injection of glucagon-like peptide-2 (GLP-2) at 9 a.m. in fasting postmenopausal women results in a dose-dependent decrease in the serum concentration of fragments derived from the degradation of the C-terminal telopeptide region of collagen type I (s-CTX), a marker of bone resorption. In contrast, GLP-2 was found to have a neutral effect on bone formation, as assessed by serum osteocalcin. Since increased s-CTX levels are normally observed at night, we conducted bedtime studies in healthy postmenopausal women. The objective was to study the effect of GLP-2 injection on bone turnover given at bedtime. A total of 81 postmenopausal women were included in two randomised placebo-controlled studies. In conclusion, we found a dose-related reduction of s-CTX after injection of GLP-2 (P < 0.05) and osteocalcin levels was increased as compared to placebo (P = 0.07) by the treatment, suggestive of a stimulative effect on bone formation. An area under the curve (AUC0-10 h) analysis for s-CTX after GLP-2 injection confirmed the dose-related decrease as compared to placebo (P < 0.05).
Similar articles
-
Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women.Bone. 2007 Mar;40(3):723-9. doi: 10.1016/j.bone.2006.09.025. Epub 2006 Nov 1. Bone. 2007. PMID: 17081815 Clinical Trial.
-
Role of gastrointestinal hormones in postprandial reduction of bone resorption.J Bone Miner Res. 2003 Dec;18(12):2180-9. doi: 10.1359/jbmr.2003.18.12.2180. J Bone Miner Res. 2003. PMID: 14672353
-
Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD.Bone. 2009 Nov;45(5):833-42. doi: 10.1016/j.bone.2009.07.008. Epub 2009 Jul 22. Bone. 2009. PMID: 19631303 Clinical Trial.
-
Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study.Bone. 2021 Nov;152:116065. doi: 10.1016/j.bone.2021.116065. Epub 2021 Jun 19. Bone. 2021. PMID: 34153529 Clinical Trial.
-
Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract.Scand J Gastroenterol. 2008 Aug;43(8):929-37. doi: 10.1080/00365520801965381. Scand J Gastroenterol. 2008. PMID: 19086164
Cited by
-
Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus.Clin Med Insights Endocrinol Diabetes. 2024 Mar 13;17:11795514241238059. doi: 10.1177/11795514241238059. eCollection 2024. Clin Med Insights Endocrinol Diabetes. 2024. PMID: 38486712 Free PMC article. Review.
-
Glucagon-Like Peptide-2 Ameliorates Age-Associated Bone Loss and Gut Barrier Dysfunction in Senescence-Accelerated Mouse Prone 6 Mice.Gerontology. 2023;69(4):428-449. doi: 10.1159/000527502. Epub 2022 Dec 5. Gerontology. 2023. PMID: 36470214 Free PMC article.
-
The Gut-Bone Axis in Diabetes.Curr Osteoporos Rep. 2023 Feb;21(1):21-31. doi: 10.1007/s11914-022-00767-2. Epub 2022 Nov 28. Curr Osteoporos Rep. 2023. PMID: 36441432 Review.
-
Bone Response to Weight Loss Following Bariatric Surgery.Front Endocrinol (Lausanne). 2022 Jul 7;13:921353. doi: 10.3389/fendo.2022.921353. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35873004 Free PMC article. Review.
-
Anabolic Bone Stimulus Requires a Pre-Exercise Meal and 45-Minute Walking Impulse of Suprathreshold Speed-Enhanced Momentum to Prevent or Mitigate Postmenopausal Osteoporosis within Circadian Constraints.Nutrients. 2021 Oct 22;13(11):3727. doi: 10.3390/nu13113727. Nutrients. 2021. PMID: 34835982 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
